Maxicin is an antimicrobial drug for systemic use. Antibacterial agents of the quinolone group. Fluoroquinolones. Moxifloxacin.
Maxicin is indicated for the treatment of the following infectious diseases:
community-acquired pneumonia; complicated skin and soft tissue infections.
Warehouse
1 ml of solution contains moxifloxacin hydrochloride (as moxifloxacin) 20 mg; excipients: sodium hydroxide, concentrated hydrochloric acid, water for injections.
Contraindication
Hypersensitivity to moxifloxacin, to other quinolones or to any of the excipients; pregnancy or breastfeeding; childhood (patients under 18 years of age); history of tendon disease/pathology associated with the use of quinolones.
Method of application
The recommended dosage regimen is 400 mg of moxifloxacin as an infusion once daily.
Initial intravenous therapy may be continued with oral moxifloxacin tablets 400 mg if clinically indicated.
In clinical trials, most patients were switched to oral moxifloxacin within 4 days (communicable disease pneumonia) or 6 days (complicated skin and soft tissue infections). The total recommended duration of intravenous and oral treatment is 7–14 days for community-acquired pneumonia and 7–21 days for complicated skin and soft tissue infections.
Application features
In some patients, moxifloxacin causes prolongation of the QTc interval on the electrocardiogram (ECG). The degree of QT prolongation may increase with increasing plasma drug concentrations due to too rapid intravenous infusion. Therefore, the recommended infusion duration should be at least 60 minutes and not exceed an intravenous dose of 400 mg once daily.
Pregnant women
Given the experimentally established risk of harmful effects of fluoroquinolones on the cartilage of weight-bearing joints in immature animals and taking into account the development of reversible joint lesions in children treated with some fluoroquinolones, moxifloxacin should not be administered to pregnant women.
Children
The efficacy and safety of the drug Maxicin® in children have not been established, therefore the use of the drug in children is contraindicated.
Drivers
Patients are advised to observe their body's reaction to moxifloxacin before driving or operating other machinery.
Overdose
No specific measures are recommended after accidental overdose. In case of overdose, symptomatic treatment should be initiated. Since QT interval prolongation is possible, ECG monitoring is required. Co-administration of activated charcoal with a dose of 400 mg moxifloxacin administered orally or intravenously reduces the systemic bioavailability of the drug by more than 80% or 20%, respectively. Administration of activated charcoal at the initial stage of absorption may be effective in preventing excessive plasma concentrations of moxifloxacin in case of overdose following oral administration.
Side effects
Infections and infestations: superinfections associated with resistant bacteria or fungi, such as oral and vaginal candidiasis.
Blood and lymphatic system disorders: anemia, leukopenia, neutropenia, thrombocytopenia, thrombocythemia, eosinophilia, prolonged prothrombin time/increased INR, increased prothrombin level/decreased INR, agranulocytosis, pancytopenia.
Immune system disorders: allergic reactions, anaphylaxis, including, in rare cases, life-threatening shock.
Storage conditions
Store at a temperature not exceeding 25°C in the original packaging. Do not freeze.
Keep out of reach of children.
